

Result update

Jamjoom Pharmaceuticals Factory

Sector : Healthcare


HOLD

29 July 2026

Target price (SAR) 149.40

Current price (SAR) 141.20

Return 5.80%



Exchange Saudi Arabia
Index weight (%) 0.2%

(mn)	SAR	USD
Market Cap	9,884	2,669
Enterprise value	9,537	2,575

Major shareholders	
Jamjoom Yousuf Moham	25.0%
Jamjoom Mahmoud Yous	10.6%
Jamjoom Ahmed Yousuf	10.6%
Others	53.8%

Valuation Summary (TTM)	
PER TTM (x)	19.7
P/Book (x)	5.8
EV/EBITDA (x)	17.0
Dividend Yield (%)	3.1
Free Float (%)	54%
Shares O/S (mn)	70
YTD Return (%)	-1%
Beta	0.7

Key ratios	2023	2024	2025
EPS (SAR)	4.18	5.09	6.63
BVPS (SAR)	20.06	21.29	24.53
DPS (SAR)	2.50	3.06	4.00
Payout ratio (%)	60%	60%	60%

Price performance (%)	1M	3M	12M
Jamjoom Pharmaceuticals F	-9%	-9%	-13%
Tadawul All Share Index	-1%	-5%	-1%

52 week	High	Low	CTL*
Price (SAR)	168.60	125.00	13.0

* CTL is % change in CMP to 52wk low

- **Jamjoom (JP) reported in line revenue in 2Q26 at SAR 445mn a growth of 12.4% YoY. Revenue from Saudi increased by 5.2%, while other geographies reported robust performance during quarter.**
- **Gross margin expanded by 265bps on the back of changes in product and geographic mix. Higher SG&A and other costs weigh on operating margins during the quarter.**
- **Net profit grew by 4.2% YoY in 2Q26, missing our estimate by 5.5%**
- **We retain our revenue forecast for 2026e at SAR 1.64bn, while net profit is reduced to SAR 500mn. Accordingly target price is lowered to SAR 149.40 per share, maintain HOLD.**



Consolidated revenue for Jamjoom Pharma grew by 12.4% YoY in 2Q26, broadly in line with our expectations. We believe this represents a commendable topline performance despite the significant slowdown in the core Saudi pharmaceutical market and trade disruptions stemming from the ongoing geopolitical impasse. Revenue from Saudi Arabia increased by 5.2% YoY, outperforming the broader domestic pharmaceutical market, which remained largely flat all through the year. The revenue growth was primarily driven by the continued strength of the core ophthalmology and dermatology segments, which expanded by 22.7% YoY and 36.9% YoY, respectively, and together accounted for 47% of the company's topline. The cardiometabolic segment also delivered healthy growth of 13.0% YoY. In contrast, the primary care segment, which contributed 29% of total revenue, declined by 5.4% YoY, partially offsetting the gains from the higher-growth therapeutic areas. Government and institutional sales remained stable, while tender business volumes increased during the quarter.

Production activity continued to improve steadily, supported by higher operational efficiencies and the scaling up of the company's three manufacturing facilities. Total production reached 95.9 million units during 1H26, representing an 11.7% YoY increase, driven primarily by the Jeddah Sterile Facility, where output surged by 145.6% YoY. Production at the Egypt facility increased by 15.7% YoY, while operations at the Jeddah Main Facility remained stable. As of the end of 2Q26, the company managed a portfolio of 148 brands. Management also highlighted that commercial production under the toll manufacturing agreement with Viatris is expected to commence in 4Q26, while production of the Pfizer portfolio is likely to begin in 3Q26 at the new KAEC facility.


Gross profit increased by 17.1% YoY during 2Q26, reflecting margin expansion driven by lower raw material costs and a more favorable product mix. However, the benefits at the gross level were partially offset by higher selling expenses, increased employee costs, higher depreciation, and elevated R&D expenditure. Consequently, the operating margin contracted by 108bps YoY, while the EBITDA margin declined by 30bps YoY. Finance costs remained broadly stable, but losses from associates weighed further on earnings. As a result, net profit increased by a modest 4.2% YoY, falling 5.5% short of our expectations.

Valuation: Jamjoom Pharma delivered a resilient performance despite a challenging operating environment. We remain constructive on the company, supported by its improving operational efficiency, scalable manufacturing platform, and growth opportunities from new strategic partnerships. While the near-term outlook may remain constrained by weak market conditions, we continue to view the long-term growth trajectory positively. Management has maintained its full-year guidance despite the seasonally weaker second half, reflecting confidence in the underlying business. Accordingly, we retain our 2026e full year revenue estimates but modestly reduce our net profit forecast to SAR 500mn to reflect continued margin pressure. We also lower our target price to SAR 149.40 per share and maintain our **Hold** rating on the stock.


Quarterly revenue growth at 12.4% YoY in 2Q26, operating margin weigh on profitability





EBITDA grows by 8.3% YoY in 2Q26



Modest net profit growth 4.2% YoY



Most segments outperform in 2Q26, core segment contribution rises to 47%





Income Statement (in SAR mn)	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Revenue	1,101	1,318	1,501	1,643	1,830	2,041	2,277	2,544
Direct Costs	-397	-498	-562	-585	-667	-744	-832	-930
Gross Profit	704	821	939	1,058	1,163	1,296	1,446	1,614
Selling and distribution	-286	-317	-357	-414	-421	-469	-524	-585
General and Admin	-66	-71	-79	-83	-92	-102	-91	-102
R&D	-33	-34	-39	-38	-46	-51	-57	-64
Impairment on receivables	-5	-18	-3	-1	-20	-22	-24	-27
Operating Profit	313	381	462	522	585	652	750	837
EBITDA	338	418	506	565	633	704	750	837
Net finance cost	-2	-17	5	2	5	5	5	5
Other income	4	19	27	5	5	4	5	5
Profit before tax	316	383	493	529	595	661	759	846
Zakat and Income Tax	-23	-26	-29	-28	-36	-40	-46	-51
Profit after tax	292	357	464	501	559	621	714	796

Balance Sheet (in SAR mn)	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Property, Plant and Equipment	696	672	689	728	790	861	985	1,123
Right-of-use asset	2	2	29	38	40	41	43	46
Intangible assets	13	12	17	17	17	17	17	17
Other non current assets	36	57	69	63	63	63	63	63
Non-current assets	747	743	805	846	910	982	1,108	1,249
Current Inventories	234	271	248	205	267	298	333	372
Trade receivables	332	444	586	822	915	1,020	1,139	1,272
Prepayments and other receivables	51	52	48	66	64	71	68	76
Other current assets	5	1	1	1	1	1	1	1
Cash and cash equivalents	284	262	358	370	330	409	496	586
Current assets	907	1,029	1,241	1,463	1,576	1,799	2,036	2,307
ASSETS	1,654	1,772	2,046	2,309	2,486	2,781	3,144	3,556
Share capital	700	700	700	700	700	700	700	700
Reserves	-41	-93	-84	-155	-155	-155	-155	-155
Retained earnings	745	884	1,101	1,322	1,573	1,859	2,199	2,567
EQUITY	1,404	1,491	1,717	1,866	2,117	2,403	2,744	3,111
Long-term loans	-	-	-	-	-	-	-	-
Lease liabilities	2	2	13	18	18	18	18	19
Employees' benefits	68	77	91	100	110	92	82	92
Non-current liabilities	70	79	104	118	128	110	100	110
Short-term loan	-	-	-	-	-	-	-	-
Lease liabilities	0	0	3	5	5	5	5	5
Trade payables and other current liabilities	154	173	186	293	200	223	249	279
Zakat and income tax provision	26	29	35	28	36	40	46	51
Current liabilities	180	202	225	325	240	268	300	334
LIABILITIES	250	281	329	443	368	378	400	444
EQUITY AND LIABILITIES	1,654	1,772	2,046	2,309	2,486	2,781	3,144	3,556

Cash Flow (In SAR Mn)	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Cash from operations	296	263	406	464	358	560	645	718
Investing cash flow	-77	-62	-69	-82	-110	-122	-182	-204
Financing cash flow	-75	-224	-242	-369	-289	-359	-376	-424
Change in cash	143	-23	96	13	-41	79	87	91
Beginning cash	141	284	262	358	370	330	409	496
Ending cash	284	262	358	370	330	409	496	586



Ratio Analysis	2023	2024	2025	2026e	2027e	2028e	2029e	2030e
Per Share								
EPS (SAR)	4.18	5.09	6.63	7.16	7.99	8.88	10.19	11.36
BVPS (SAR)	20.06	21.29	24.53	26.66	30.25	34.33	39.20	44.45
DPS (SAR)	2.50	3.06	4.00	4.40	4.79	5.33	6.12	6.82
FCF per share (SAR)	3.12	2.87	4.82	5.45	3.55	6.25	6.61	7.36
Valuation								
Market cap (SAR mn)	7,994	10,654	10,920	9,884	9,884	9,884	9,884	9,884
EV (SAR mn)	7,712	10,394	10,579	9,537	9,577	9,498	9,411	9,321
EBITDA (SAR mn)	338	418	506	565	633	704	750	837
P/E (x)	27.3	29.9	23.5	19.7	17.7	15.9	13.9	12.4
EV/EBITDA (x)	22.8	24.9	20.9	16.9	15.1	13.5	12.6	11.1
Price/Book (x)	5.7	7.1	6.4	5.3	4.7	4.1	3.6	3.2
Dividend Yield (%)	2.2%	2.0%	2.6%	3.1%	3.4%	3.8%	4.3%	4.8%
Price to sales (x)	7.3	8.1	7.3	6.0	5.4	4.8	4.3	3.9
EV to sales (x)	7.0	7.9	7.0	5.8	5.2	4.7	4.1	3.7
Liquidity								
Cash Ratio (x)	1.6	1.3	1.6	1.1	1.4	1.5	1.7	1.8
Current Ratio (x)	5.0	5.1	5.5	4.5	6.6	6.7	6.8	6.9
Quick Ratio (x)	3.7	3.8	4.4	3.9	5.4	5.6	5.7	5.8
Returns Ratio								
ROA (%)	17.7%	20.1%	22.7%	21.7%	22.5%	22.3%	22.7%	22.4%
ROE (%)	20.8%	23.9%	27.0%	26.8%	26.4%	25.9%	26.0%	25.6%
ROCE (%)	19.8%	22.7%	25.5%	25.2%	24.9%	24.7%	25.1%	24.7%
Cash Cycle								
Inventory turnover (x)	1.7	1.8	2.3	2.9	2.5	2.5	2.5	2.5
Accounts Payable turnover (x)	2.6	2.9	3.0	2.0	3.3	3.3	3.3	3.3
Receivables turnover (x)	2.9	2.7	2.4	1.9	1.9	1.9	1.9	1.9
Inventory days	215	199	161	128	146	146	146	146
Payable Days	142	127	121	183	110	110	110	110
Receivables days	110	123	143	183	183	183	183	183
Cash Cycle	183	195	183	128	219	219	219	219
Profitability Ratio								
Net Margins (%)	26.6%	27.0%	30.9%	30.5%	30.6%	30.4%	31.3%	31.3%
EBITDA Margins (%)	30.7%	31.7%	33.7%	34.4%	34.6%	34.5%	32.9%	32.9%
PBT Margins (%)	28.7%	29.0%	32.9%	32.2%	32.5%	32.4%	33.3%	33.3%
EBIT Margins (%)	28.5%	28.9%	30.8%	31.8%	32.0%	32.0%	32.9%	32.9%
Effective Tax Rate (%)	7.4%	6.8%	5.9%	5.3%	6.0%	6.0%	6.0%	6.0%
Leverage								
Total Debt (SAR, mn)	2.4	2.1	16.4	22.7	22.8	22.9	23.0	23.1
Net Debt (SAR, mn)	-282	-260	-341	-347	-307	-386	-473	-563
Debt/Equity (x)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net Debt/Equity (x)	-0.2	-0.2	-0.2	-0.2	-0.1	-0.2	-0.2	-0.2


Key contacts

Research Team

Joice Mathew	Manna Thomas ACCA	Contact Address
Sr. Manager - Research	Research Associate	P. O Box: 2566; P C 112
E-Mail: joice@usoman.com	Email: manna.t@usoman.com	Sultanate of Oman
Tel: +968 2476 3311	Tel: +968 2476 3347	Tel: +968 2476 3300

Rating Criteria and Definitions

Rating



Rating Definitions

Strong Buy	This recommendation is used for stocks whose current market price offers a deep discount to our 12-Month target price and has an upside potential in excess of 20%
Buy	This recommendation is used for stocks whose current market price offers a discount to our 12-Month target price and has an upside potential between 10% to 20%
Hold	This recommendation is used for stocks whose current market price offers a discount to our 12-Month target price and has an upside potential between 0% to 10%
Neutral	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential between 0% to -10%
Sell	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential between -10% to -20%
Strong Sell	This recommendation is used for stocks whose current market price offers a premium to our 12-Month target price and has a downside side potential in excess of 20%
Not rated	This recommendation used for stocks which does not form part of Coverage Universe

Disclaimer

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions. Opinion expressed is our current opinion as of the date appearing on this material only. We do not undertake to advise you as to any change of our views expressed in this document. While we endeavor to update on a reasonable basis the information discussed in this material, United Securities, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and are for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company takes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

Recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. United Securities LLC, and affiliates, including the analyst who has issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions. United Securities LLC and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.